The grant will support a Phase I study of an anti-CD64 CAR T-cell therapy in patients with acute myeloid leukemia.
The partners want to develop personalized therapeutics and diagnostics based on insights derived from the Middle Eastern biorepository.
The trials will test the ability of the firm's fluorine-18 labeled PET tracer to detect FAP-expressing tumor cells in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback